Xagrid
anagrelide
Table of contents
Overview
Xagrid is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets in the blood). ‘Essential’ means that the disease has no obvious cause.
Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are ‘at risk’ because of their age (over 60 years), very high platelet counts or previous clotting problems.
Xagrid contains the active substance anagrelide.
Authorisation details
Product details | |
---|---|
Name |
Xagrid
|
Agency product number |
EMEA/H/C/000480
|
Active substance |
Anagrelide
|
International non-proprietary name (INN) or common name |
anagrelide
|
Therapeutic area (MeSH) |
Thrombocythemia, Essential
|
Anatomical therapeutic chemical (ATC) code |
L01XX35
|
Publication details | |
---|---|
Marketing-authorisation holder |
Takeda Pharmaceuticals International AG Ireland Branch
|
Revision |
40
|
Date of issue of marketing authorisation valid throughout the European Union |
15/11/2004
|
Contact address |
Block 2 Miesian Plaza |
Product information
16/02/2023 Xagrid - EMEA/H/C/000480 - IAIN/0100/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antineoplastic agents
Therapeutic indication
Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.
An at-risk patient
An at-risk ET is defined by one or more of the following features:
- >60 years of age or;
- a platelet count >1000 x 109/l or;
- a history of thrombohaemorrhagic events.